Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions in the response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium comprising the addition of an amino acid mixture to the sugar-rich medium used to grow the plant cells.

Abstract: The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human ?1,4-galactosyltransferase gene; a cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-lymphocyte anti-gen A-immunoglobulin (CTLA4Ig) fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a plant-derived recombinant human CTLA4Ig (CTLA4Igp) fusion protein with a human glycan structure using the same. The plant cell-derived recombinant human CTLA4Ig fusion protein (CTLA4Igp), which has a human glycan structure and is produced according to the present invention, exhibits an improved in vivo half life as compared to conventional plant-derived proteins, due to the presence of a human-like glycan structure.

Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions or in response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium. The method comprises 1) culturing transgenic plant cells in a sugar-rich medium to grow plant cells; and 2) culturing the transgenic plant cells with addition of an amino acid mixture to the culture of Step 1 without exchange of a cell growth medium with a sugar-depleted medium, thereby expressing a target protein.

Abstract: An antibacterial composition for external application, particularly, a remedial formulation for external use containing fluconazole is disclosed. The formulation comprises a base material, 0.1-5.0 percent by weight of fluconazole and 1.0-40.0 percent by weight of any one compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol based on weight of the base material. The composition according to the present invention has various advantages of a favorable absorption into a system through the skin of a human body and delivery of active material into horny layer of the skin, a reduced skin stimulation and an excellent stability. Therefore, the composition is efficiently useable in a medical treatment application for dermatomycosis-related infectious diseases including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and/or candidiasis and the like.

Abstract: A process for preparing pyrimidinone compound and salts thereof The method of the present invention enables the convenience to produce the pyrimidinone derivatives in high yields, which pyrimidinone compounds are useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors.

Abstract: A process for preparing pyrimidinone compound and salts thereof The method of the present invention enables the convenience to produce the pyrimidinone derivatives in high yields, which pyrimidinone compounds are useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors.

Abstract: An antibacterial composition for external application, particularly, a remedial formulation for external use containing fluconazole is disclosed. The formulation comprises a base material, 0.1-5.0 percent by weight of fluconazole and 1.0-40.0 percent by weight of any one compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol based on weight of the base material. The composition according to the present invention has various advantages of a favorable absorption into a system through the skin of a human body and delivery of active material into horny layer of the skin, a reduced skin stimulation and an excellent stability. Therefore, the composition is efficiently useable in a medical treatment application for dermatomycosis-related infectious diseases including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and/or candidiasis and the like.

Abstract: Transdermal gels comprising (1) ketoprofen as an effective component, (2) poloxamer, (3) one or more agents selected from ethyl alcohol, isopropyl alcohol, propylene glycol, polyethylene glycol and glycerin, (4) one or more agents selected from the group consisting of lauric acid, oleic acid, capric acid, myristic acid, lauryl alcohol, oleyl alcohol and menthol, (5) water or a buffer solution. The gels form thin and pliable films, which are easily washable with water. They possess prolonged antiinflammatory and analgesic activities and physicochemical stability with less systemic side effects and gastric irritation.